Lucid Diagnostics Inc. reports developments in commercial-stage cancer prevention diagnostics for patients with gastroesophageal reflux disease who are at risk for esophageal precancer and esophageal adenocarcinoma. The company, a subsidiary of PAVmed Inc., markets the EsoGuard Esophageal DNA Test and uses the EsoCheck Esophageal Cell Collection Device to collect samples through a brief, noninvasive office procedure.
Recurring updates cover EsoGuard commercialization, healthcare-system access, clinical evidence for esophageal precancer detection, quarterly business results, cash resources, and conference presentations. Lucid news also includes capital actions such as registered common stock offerings and related use of proceeds for working capital and general corporate purposes.
Lucid Diagnostics, a cancer prevention medical diagnostics company, partners with the Esophageal Cancer Action Network (ECAN) to raise awareness during Esophageal Cancer Awareness Month. The partnership aims to educate about the link between heartburn and esophageal cancer, promoting early detection for prevention. Public service videos are being displayed in Times Square, emphasizing the importance of screening for those at risk.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.